Increased melanoma risk in Parkinson disease: A prospective clinicopathological study

John M. Bertoni, John Philip Arlette, Hubert H. Fernandez, Cheryl Fitzer-Attas, Karen Frei, Mohamed N. Hassan, Stuart H. Isaacson, Mark F. Lew, Eric Molho, William G. Ondo, Tania J. Phillips, Carlos Singer, James P. Sutton, John E. Wolf

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

Objective: To evaluate the possible association of Parkinson disease (PD) and melanoma in North America. Design, Setting, and Patients: Thirty-one centers enrolled patients with idiopathic PD. At visit 1, a neurologist obtained a medical history. At visit 2, a dermatologist recorded melanoma risk factors, performed a whole-body examination, and performed a biopsy of lesions suggestive of melanoma for evaluation by a central dermatopathology laboratory. We compared overall prevalence of melanoma with prevalence calculated from the US Surveillance Epidemiology and End Results (SEER) cancer database and the American Academy of Dermatology skin cancer screening programs. Results: A total of 2106 patients (mean [SD] age, 68.6 [10.6] years; duration of PD, 7.1 [5.7] years) completed the study. Most (84.8%) had received levodopa. Dermatology examinations revealed 346 pigmented lesions; dermatopathological findings confirmed 20 in situ melanomas (0.9%) and 4 invasive melanomas (0.2%). In addition, histories revealed 68 prior melanomas (3.2%). Prevalence (5-year limited duration) of invasive malignant melanoma in the US cohort of patients with PD (n=1692) was 2.24-fold higher (95% confidence interval, 1.21-4.17) than expected in age- and sex-matched populations in the US SEER database. Age- or sex-adjusted relative risk of any melanoma for US patients was more than 7 times that expected from confirmed cases in American Academy of Dermatology skin cancer screening programs. Conclusions: Melanoma prevalence appears to be higher in patients with PD than in the general population. Despite difficulties in comparing other databases with this study population, the study supports increased melanoma screening in patients with PD.

Original languageEnglish (US)
Pages (from-to)347-352
Number of pages6
JournalArchives of neurology
Volume67
Issue number3
DOIs
StatePublished - Mar 1 2010

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Increased melanoma risk in Parkinson disease: A prospective clinicopathological study'. Together they form a unique fingerprint.

  • Cite this

    Bertoni, J. M., Arlette, J. P., Fernandez, H. H., Fitzer-Attas, C., Frei, K., Hassan, M. N., Isaacson, S. H., Lew, M. F., Molho, E., Ondo, W. G., Phillips, T. J., Singer, C., Sutton, J. P., & Wolf, J. E. (2010). Increased melanoma risk in Parkinson disease: A prospective clinicopathological study. Archives of neurology, 67(3), 347-352. https://doi.org/10.1001/archneurol.2010.1